Years of dedicated research at Universitat Pompeu Fabra laboratories of Proteomics/Protein Chemistry and Neurophar, in collaboration with other institutions, led to the breakthrough discovery of the CB1R-5HT2AR complex (Viñals et al., 2015).
Building on this finding, the scientific team developed and validated DRT-101 as a fully druggable peptide disruptor of CB1R-5HT2AR (Gallo et al., 2021).
This phase is led by an expert entrepreneur in start-up initiatives to address unmet medical needs.
In January 2023, Disrupt Therapeutics officially launched, aiming to provide with advanced solutions for CUD and cognitive protection.
Co-founder &
Chief Executive Officer
Co-founder &
peptide drug specialist
Partner &
Chief Operating Officer
Our primary goal is to advance the preclinical and clinical development of DRT-101, as an innovative therapeutic solution for CUD, a condition for which no pharmacotherapies are currently available.
Our ultimate mission is to offer individuals affected by CUD a route to a brighter, healthier future, helping them regain control and improve their well-being.
Copyright © 2025 Disrupt Therapeutics.
